The brief
- May 2025: first-ever prime-editing patient data (PM359) restored immune-cell function; the drug was then shelved for business reasons.
- FDA cleared a trial of PM577a for Wilson disease in Jul 2026; dosing expected in H2 2026.
Programs
Prime Medicine, two programs
Updated 23 Jul 2026PM577a (Wilson disease)Fat bubbles carry a prime editor to the liver to fix the most common Wilson disease typo in the West, so the liver can clear copper again.ResearchNextFirst patient dosed · 2026Updated 23 Jul 2026View program →PM359 (CGD)A patient's own stem cells are prime-edited to fix a typo behind chronic granulomatous disease, so their white blood cells can kill germs again.ProtoUpdated 22 Jun 2026View program →
Research · Proto · Pilot · Deploy · Scaling
Research & demos
- Oct 2019paperSearch-and-replace genome editing without double-strand breaks or donor DNA (Nature) (opens doi.org)
Anzalone et al. introduced prime editing.
Upcoming catalysts
- 2027First clinical data from the PM577a Phase 1/2 trial (company guidance)PM577a (Wilson disease)by ~15 mo
Peers
Company & funding
- Listed
- PRME (opens google.com)NASDAQ
- HQ
- US
- Founded
- 2019